Ocumetics Technology

Ocumetics Announces Completion of Unit Private Placement

Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it has completed the private placement previously announced by the Corporation on November 15, 2023 and December 21, 2023.

The Corporation issued an aggregate of 1,301,875 units (“ Units ”) pursuant to the private placement, at a price of $0.32, for total gross proceeds of $416,600.00. Each Unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and one-half of one common share purchase warrant. Each whole warrant (“ Warrant ”) entitles the holder to purchase one additional Common Share at an exercise price of $0.64 for a period of two years from the date of issuance of the Warrant.

The Corporation paid finders fees to Leede Jones Gable Inc. consisting of cash commissions of $200.00.

100% of the net proceeds are expected to be used to fund the Corporation’s first in-human clinical trials and for ongoing research and development, although the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

All securities issued under the Private Placement are subject to a hold period of four months and one day.

Closing of the Private Placement was subject to the conditional approval from the TSX Venture Exchange, which was obtained.

Related Party Transaction

Dean Burns, the President and CEO of the Corporation, Garth Webb, the Chief Scientific Officer of the Corporation and Roger Jewett, the CFO of the Corporation, participated in the Private Placement. The Private Placement was therefore a “Related Party Transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“ MI 61-101 ”). The Corporation relied upon the exemptions from the minority shareholder approval and valuation requirements set out in Sections 5.7(1)(a) and 5.5(a), respectively, of MI 61-101. The Private Placement, including the subscriptions of Messrs Burns, Webb and Jewett, was approved unanimously by the directors of the Corporation by resolution.

A material change report regarding the Private Placement was not filed 21 days before the completion of the Private Placement as 21 days prior to the completion of the Private Placement, completion of the Private Placement was uncertain and therefore did not at that time constitute a material change.

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns Dayton Marks

President and CEO Director

(817) 874-7564 (778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development and clinical trials to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Source

Click here to connect with Ocumetics Technology Corp. ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) to receive an Investor Presentation

OTC:CA
Ocumetics Technology

Ocumetics Technology Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Ocumetics Technology

Ocumetics Technology


Keep reading...Show less
Ocumetics Announces Extension of Private Placement

Ocumetics Announces Extension of Private Placement

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - December 21, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private placement announced on November 15, 2023. The new closing deadline for the private placement is January 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

(TheNewswire)

Ocumetics Technology Corp.

Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned

Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - December 7, 2023 - Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in the field of ophthalmic innovation, proudly confirms the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Continues to Meet Significant Development Milestones; Lens Design Optimized for Upcoming First in Human Study

Ocumetics Continues to Meet Significant Development Milestones; Lens Design Optimized for Upcoming First in Human Study

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta September 18, 2023. Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in in the field of ophthalmic innovation, proudly confirms a remarkable achievement in the optimization of its vision correction technology - the Ocumetics Accommodating Lens. Through rigorous research and development efforts over the past two years, Ocumetics has modified its lens design five times, ultimately arriving at its groundbreaking final lens configuration version 10.5. Lens version 10.5 has been tested in vitro and in an animal model, and will be used in Ocumetics' upcoming human clinical trials.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors

Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - September 1, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in advanced eye care solutions, is pleased to announce the appointment of Dr. Doyle Stulting and Dr. Bart McRoberts to its Board of Directors. With their unparalleled expertise in ophthalmology and vision research, Drs. Stulting and McRoberts bring a wealth of knowledge that will help drive Ocumetics' innovation and commitment to improving eye care globally.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Appendix 4D and Half Yearly Accounts

Cleo Diagnostics Limited (ASX:COV) (Cleo, or the Company) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker. Cleo's first test - AdnexaSureTM is designed to distinguish benign from malignant growths and will be compatible with standard diagnostic laboratory workflows worldwide.

Keep reading...Show less

Thermo Fisher Scientific to Present at TD Cowen 44th Annual Health Care Conference on March 6, 2024

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the TD Cowen Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. (EST).

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Inc. Celebrates its First Decade of Success

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.

Since its inception on February 28, 2014, Knight has delivered significant milestones and made progress on its strategy of building a profitable pan-American (ex US) company commercializing both innovative and branded generic pharmaceuticals products and talented people.

Key Accomplishments:

  1. Built a Unique Platform in Canada & Latin America

    Knight has invested over $925 million to build its unique pan-American (ex US) platform of innovative and branded generic pharmaceuticals. Today, Knight has over 700 talented employees operating in Canada and 10 Latin American markets. Knight is a fully integrated company with capabilities spanning regulatory, quality, pharmacovigilance, compliance, medical, market access, marketing, sales and supply chain in all 11 countries, as well as branded generic development and manufacturing capabilities in Argentina.

  2. Delivered Profitable Growth

    Knight has delivered consecutive years of record revenues since 2014 and EBITDA since 2019. As at Q3-23, Knight delivered trailing twelve months revenue of over $335 million and adjusted EBITDA of over $61 million representing a respective CAGR of 22.7% and 20.7% since the 100% acquisition of Grupo Biotoscana in 2020.

  3. Partner of Choice

    Knight has a platform which offers a one-stop-shop solution for biotech and pharmaceutical companies seeking a commercialization partner in our 11 territories. Since the completion of the acquisition of Biotoscana, Knight has entered into 11 new partnerships for 13 innovative and branded generic products.

  4. Strong Pipeline Expected to Deliver Over $120 Million in Peak Revenues

    Knight has assembled a strong pipeline across our territories of 17 products which include products in early launch or in various stages of development. The products are projected to be launched by 2028 and Knight has advanced the pipeline with the submission of 8 of these products for regulatory approval in at least one country.

When reflecting on Knight's accomplishments since founding, Jonathan Ross Goodman, Knight's Executive Chairman, said "We are doing exactly what we said we would do in 2014 – we built a fabulous pharmaceutical company with talented motivated Knights delivering pharmaceuticals to Canadians and Latin Americans. During these 10 years, we have generated $379 million 1 and we will continue to strengthen on our platform and bring shareholder value."

"I am incredibly proud of what we have accomplished to date and I am excited about the future achievements that we will deliver to all of our stakeholders. None of this would be possible without the fantastic team that we have in place across all our countries. Their unwavering commitment and dedication to serving patients have been instrumental in shaping Knight as the partner of choice for Canada and Latin America," said Samira Sakhia, President and Chief Executive Officer.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca .

Forwa rd-Looking Statements

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2022, as filed on www.sedarplus.ca . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

CONTACT INFORMATION FOR KNIGHT:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. +598.2626.2344
F: 514.481.4116
Email: IR@knighttx.com Email: IR@knighttx.com
Website: www.knighttx.com Website: www.knighttx.com

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

  • 8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study
  • Orchestra BioMed is actively enrolling patients in the BACKBEAT pivotal study of AVIM therapy in hypertensive pacemaker patients

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of new data demonstrating the long-term effect of atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT™) on generating clinically-meaningful reductions in 24-hour ambulatory systolic blood pressure ("aSBP") in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. The data were presented by Avi Fischer, M.D., Senior Vice President of Medical Affairs and Innovation of Orchestra BioMed in a scientific session at the Innovation in Cardiovascular Interventions ("ICI") 2024 Meeting.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

  • Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis
  • Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis
  • Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basis
  • GAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for the year
  • Adjusted EBITDA Attributable to Bausch Health Companies Inc. 1 of $869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results

"I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.

"This submission of fostamatinib demonstrates Knight's continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Ocumetics Technology

Ocumetics Technology Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×